

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Medical technologies evaluation programme

### Equality impact assessment: Guidance development

#### MT450 Danis stent for acute oesophageal variceal bleeds

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

#### Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No additional equality issues were identified by stakeholders during scoping; however, equality considerations were highlighted. Danis stent is intended for use in people aged 16 years and over with acute refractory variceal bleeding. Oesophageal variceal bleeding is a common and life-threatening complication of cirrhosis in people with chronic liver disease. Some people with chronic liver disease may be considered disabled under the Equality Act if their condition 'has a substantial and long-term adverse effect on their ability to carry out normal day-to-day activities'. Age and disability are protected characteristics under the Equality Act 2010. These considerations were acknowledged by the committee at the beginning of the committee meeting.

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No other potential equality issues have been identified in the sponsors submission

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No other equality issues were identified by the committee..

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

n/a

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No equality issues related to the recommendations were identified.

**Approved by Associate Director:** Rebecca Albrow

**Date:** 14/01/21

## Medical technology guidance document

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to access for the specific group?

3. If the recommendations have changed after consultation, is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

